SODIUM BICARBONATE Drug Patent Profile
✉ Email this page to a colleague
When do Sodium Bicarbonate patents expire, and when can generic versions of Sodium Bicarbonate launch?
Sodium Bicarbonate is a drug marketed by Exela Pharma, Hospira, Intl Medication Sys, Nivagen Pharms Inc, Omnivium Pharms, Steriscience, and Abbott. and is included in twelve NDAs.
The generic ingredient in SODIUM BICARBONATE is sodium bicarbonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the sodium bicarbonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Bicarbonate
A generic version of SODIUM BICARBONATE was approved as sodium bicarbonate by HOSPIRA on March 4th, 2016.
Summary for SODIUM BICARBONATE
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 12 |
Finished Product Suppliers / Packagers: | 13 |
Raw Ingredient (Bulk) Api Vendors: | 168 |
Clinical Trials: | 260 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SODIUM BICARBONATE |
DailyMed Link: | SODIUM BICARBONATE at DailyMed |
Recent Clinical Trials for SODIUM BICARBONATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Taipei Medical University Shuang Ho Hospital | Phase 2 |
University of Southern California | Phase 2 |
Australian and New Zealand Intensive Care Research Centre | Phase 3 |
Pharmacology for SODIUM BICARBONATE
Drug Class | Osmotic Laxative |
Mechanism of Action | Osmotic Activity Alkalinizing Activity |
Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |